Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab—two monoclonal antibody treatments under Food and Drug Administration emergency use authorization—keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.

source https://medicalxpress.com/news/2021-08-monoclonal-antibody-treatment-combo-hospitalization.html